Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSD-201
- Development stage
- Phase 1
- Lead developer
- Zhongshan Hengsai Biological Technology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
KSD-201 is an autologous dendritic cell vaccine developed by Wuhan Kangshengda Medical Technology for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The therapeutic process involves the collection of a patient's peripheral blood mononuclear cells (PBMCs), from which monocytes are isolated and differentiated into dendritic cells ex vivo. These mature dendritic cells are then administered back to the patient via subcutaneous injection, typically near the axillary or inguinal lymph nodes, to act as professional antigen-presenting cells. The goal of the therapy is to stimulate a systemic, targeted immune response against malignant tumor cells. A clinical study (NCT06708936) was planned to evaluate the safety, tolerability, and preliminary efficacy of KSD-201 in patients with advanced ccRCC, but the trial was withdrawn before enrollment began.
- Other names
- autologous dendritic cell vaccine
Beyond the preview
Go deeper on KSD-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSD-201.